Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

456 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation.
Brown BP, Zhang YK, Westover D, Yan Y, Qiao H, Huang V, Du Z, Smith JA, Ross JS, Miller VA, Ali S, Bazhenova L, Schrock AB, Meiler J, Lovly CM. Brown BP, et al. Among authors: meiler j. Clin Cancer Res. 2019 Jun 1;25(11):3341-3351. doi: 10.1158/1078-0432.CCR-18-3829. Epub 2019 Feb 22. Clin Cancer Res. 2019. PMID: 30796031 Free PMC article.
Structural models for the KCNQ1 voltage-gated potassium channel.
Smith JA, Vanoye CG, George AL Jr, Meiler J, Sanders CR. Smith JA, et al. Among authors: meiler j. Biochemistry. 2007 Dec 11;46(49):14141-52. doi: 10.1021/bi701597s. Epub 2007 Nov 14. Biochemistry. 2007. PMID: 17999538 Free PMC article.
EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.
Gallant JN, Sheehan JH, Shaver TM, Bailey M, Lipson D, Chandramohan R, Red Brewer M, York SJ, Kris MG, Pietenpol JA, Ladanyi M, Miller VA, Ali SM, Meiler J, Lovly CM. Gallant JN, et al. Among authors: meiler j. Cancer Discov. 2015 Nov;5(11):1155-63. doi: 10.1158/2159-8290.CD-15-0654. Epub 2015 Aug 18. Cancer Discov. 2015. PMID: 26286086 Free PMC article.
EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.
Konduri K, Gallant JN, Chae YK, Giles FJ, Gitlitz BJ, Gowen K, Ichihara E, Owonikoko TK, Peddareddigari V, Ramalingam SS, Reddy SK, Eaby-Sandy B, Vavalà T, Whiteley A, Chen H, Yan Y, Sheehan JH, Meiler J, Morosini D, Ross JS, Stephens PJ, Miller VA, Ali SM, Lovly CM. Konduri K, et al. Among authors: meiler j. Cancer Discov. 2016 Jun;6(6):601-11. doi: 10.1158/2159-8290.CD-16-0075. Epub 2016 Apr 21. Cancer Discov. 2016. PMID: 27102076 Free PMC article.
An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.
Hanker AB, Brewer MR, Sheehan JH, Koch JP, Sliwoski GR, Nagy R, Lanman R, Berger MF, Hyman DM, Solit DB, He J, Miller V, Cutler RE Jr, Lalani AS, Cross D, Lovly CM, Meiler J, Arteaga CL. Hanker AB, et al. Among authors: meiler j. Cancer Discov. 2017 Jun;7(6):575-585. doi: 10.1158/2159-8290.CD-16-1431. Epub 2017 Mar 8. Cancer Discov. 2017. PMID: 28274957 Free PMC article.
PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3Kα Inhibitors.
Croessmann S, Sheehan JH, Lee KM, Sliwoski G, He J, Nagy R, Riddle D, Mayer IA, Balko JM, Lanman R, Miller VA, Cantley LC, Meiler J, Arteaga CL. Croessmann S, et al. Among authors: meiler j. Clin Cancer Res. 2018 Mar 15;24(6):1426-1435. doi: 10.1158/1078-0432.CCR-17-2141. Epub 2017 Dec 28. Clin Cancer Res. 2018. PMID: 29284706 Free PMC article.
456 results